Update, November 5, 2026
Rulemaking has not finished, but the interval this post described got shorter for six peptides. On October 28, HHS announced it does not intend to take enforcement action against 503A compounding of BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon by state-licensed pharmacies, federal facilities and licensed physicians, if ten conditions are met. Emideltide (DSIP), the seventh peptide reviewed in July, is excluded. The conditions include one active ingredient per product (no BPC-157 and TB-500 blends), routes limited per peptide, API from an FDA-registered facility with a valid certificate of analysis, MedWatch and state reporting of serious adverse events, a fixed label statement, a 510(k)-cleared syringe as the only device, and a patient-specific prescription. 503B outsourcing facilities are not covered.
The Federal Register notice (October 30) calls the policy a draft and an interim policy with a two-week comment period; law firms differ on whether to call it in effect. FDA's reviewers had recommended against all six, and HHS can revise or withdraw the policy. The peptides are still not on the 503A bulks list and not FDA-approved. On November 2, LegitScript said a covered peptide offered within the conditions should not by itself block certification. A second advisory committee meeting on five more peptides is expected before the end of February 2027, with no date set (Holland & Knight). What to do with all this is in our launch checklist.
The meeting happened. The category exhaled. Now the clock runs.
On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for potential inclusion on the compounding-eligible list: BPC-157, KPV, TB-500, and MOTS-c on day one; DSIP, Semax, and Epitalon on day two. It was the most anticipated regulatory event in consumer longevity this year, and if you followed along, you watched an entire industry refresh a livestream.
Here is the structural truth that matters more than any individual vote, and the one worth explaining to your team and your patients: advisory committee votes do not change what is legal to compound. They feed FDA's decision-making, which then moves through rulemaking, proposals, comment periods, final determinations, before any peptide's compounding status actually changes. The agency's own briefing materials heading into the meeting signaled a skeptical starting posture, and the committee has more peptides queued for a future session.
Translation for operators: whatever happened in the room, you are now standing at the start of a rulemaking interval measured in quarters, with a clearer map than you had before the meeting. That interval is a gift to anyone who uses it. Most will not. This post is the roadmap for those who will.
Our pre-meeting watchlist, with the compound-by-compound background, is at Regenerative Peptides in 2026.
Updated September 22, 2026: added the status as of September (no updated 503A bulks list, nothing newly compoundable, the April 15 removal of twelve peptides from Category 2, the votes as reported by press) and an FAQ on whether telehealth can prescribe peptides.
Status as of September 2026
As of September, nothing the committee discussed had become compoundable (for the October 28 change, see the update at the top). The dated record:
| Date | What happened | Effect on what a 503A pharmacy can compound |
|---|---|---|
| April 15, 2026 (effective April 22) | FDA removed twelve peptides from 503A Category 2 (Docket FDA-2025-N-6895): BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTs-c, Semax, TB-500 | None was added to the bulks list; nothing became compoundable |
| July 23 to 24, 2026 | PCAC discussed BPC-157, KPV, TB-500, and MOTs-c, then emideltide (DSIP), Semax, and Epitalon, for the 503A bulks list | Advisory only. Press (Time, July 23) reported favorable votes on six of seven; FDA's meeting page posts no tallies |
| September 22, 2026 | No updated bulks list published | Nothing newly prescribable |
Hims & Hers told investors in August that six peptides are ready to launch once FDA acts, and Leerink puts the telehealth peptide market at $2.2 billion by 2027, so the demand side is not waiting. On the supply side, our treatments directory already lists sermorelin, NAD+, and PT-141 programs, which are launchable today; what a given pharmacy will compound beyond those depends on its own read of the current bulks-list status, and we would ask for that read in writing before building a program around it.
What the interval is for
Think of the next four to six quarters as three parallel builds.
Build one: governance that would survive an inspection
When peptide compounding rules eventually settle, in whatever direction, the brands that get to move immediately are the ones whose clinical governance already exists: a medical director with genuine authority, written protocols with eligibility and refusal criteria, documentation habits that treat every prescription as reviewable, and a lab-first clinical model rather than a checkout-first one.
Building that takes a quarter if you are focused, and it is not wasted work in any regulatory scenario, because it is the same governance that hormone care, metabolic care, and every other serious program requires. The blueprints are in Clinical Protocols for DTC Telehealth and Building a Clinical Advisory Board.
Build two: the audience that already trusts you
Peptide search demand did not wait for the committee and will not wait for rulemaking. Right now, the information landscape for these compounds is a swamp of vendor hype and forum lore, which means the first brand to publish genuinely credible, clinician-reviewed education owns the category's attention long before it can own its prescriptions.
The content plan writes itself from patient questions: what the committee actually decided, what is legal today versus rumored, what the evidence base honestly says compound by compound, what a responsible program will look like when rules allow. Structured, dated, plainly sourced content on exactly these questions is also what AI answer engines cite when users ask, and they are asking constantly. The mechanics are in Generative Engine Optimization for Telehealth.
Tissue and Gut Recovery
The anchor group of a recovery-focused telehealth program. Most often paired together in clinical protocols.
Most discussed peptide in the recovery category. Studied for soft tissue, joint, ligament, and GI mucosa support.
Most often paired with BPC-157. Positioned around wound healing, soft tissue flexibility, and post-injury recovery.
Anti-inflammatory peptide, with patient interest concentrated around gut health and certain skin conditions.
Build three: the adjacent program that serves the demand now
The peptide-curious patient wants recovery, energy, cognition, and healthy aging. Peptides are one path to those goals; they are not the only one, and they are not the only thing this patient will buy. The compliant move during the interval is the adjacent program: hormone optimization, metabolic care including low-dose protocols, NAD-adjacent offerings where appropriate, sleep and recovery programs, all wrapped in the membership architecture longevity patients prefer.
Run this way, the brand serves the actual demand today, builds the patient relationships and the diagnostic spine, and holds a natural expansion slot for compounds as rules permit. The full architecture is in The Membership-Model Longevity Clinic, with the compound landscape in The Longevity Stack and Peptide Therapy Program Design in Telehealth.
The day-one advantage, engineered in advance
Somewhere ahead sits a day when the rules change, for some compound, in some direction. Reconstruct what day one looks like for two hypothetical brands:
| Brand that waited | Brand that built | |
|---|---|---|
| Governance | Starts drafting protocols | Adds one protocol to an existing framework |
| Providers | Recruits and trains | Briefs clinicians already running adjacent programs |
| Patients | Starts acquiring | Emails a waitlist that has read its content for a year |
| Content | Publishes its first explainer | Updates the page every AI engine already cites |
| Infrastructure | Evaluates platforms | Flips on a program its platform already supports |
| Pharmacy | Begins partner diligence | Activates a lane in an existing routing setup |
The gap between those columns is roughly two quarters of revenue and an unassailable credibility lead, and every row of the right column is buildable now, in full compliance, with no bet on any particular regulatory outcome.
The infrastructure row deserves emphasis because it is the least reversible. A platform that handles multi-program membership care, lab trending, specialty pharmacy routing, and fast program spin-up makes the day-one flip a configuration change. A single-program stack makes it a migration. The difference is the thesis of Diversify Like a Platform and the evaluation lens from How to Pick a White-Label Telehealth Platform in 2026.
What to tell patients right now
A short, honest script earns more trust than any marketing this quarter:
The committee reviewed seven peptides and its votes now feed a longer FDA process; nothing changed overnight. Some compounds remain unavailable through legitimate channels, and anyone selling them today as "research chemicals" is not a care provider. Here is what we offer now that serves the same goals, here is the evidence behind it, and here is where we will announce changes the moment rules allow. Join the list.
Brands delivering that message are doing something quietly powerful: converting a regulatory pause into a demonstration of exactly the credibility that will matter when the pause ends.
FAQ
Did the FDA legalize BPC-157 or other peptides at the July 2026 meeting? No. The advisory committee's July 23 to 24 review produced recommendations, not legal changes. Any change to compounding eligibility flows through subsequent FDA rulemaking, which typically runs months to years.
Which peptides did the FDA committee review in July 2026? BPC-157, KPV, TB-500, and MOTS-c on the first day; DSIP, Semax, and Epitalon on the second. Additional peptides are queued for a future committee session.
When will peptide compounding rules actually change? No date is set. Committee input feeds FDA determinations that move through proposal and comment stages; operators should plan in quarters, not weeks, and build during the interval rather than waiting for certainty.
Can telehealth programs offer peptides today? Only within current compounding rules. Since October 28, 2026, those include six peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon) under HHS's interim enforcement-discretion conditions; others, such as DSIP, LL-37 and GHK-Cu, remain outside legitimate channels. Serious programs serve the underlying demand through compliant adjacent offerings, hormone, metabolic, and recovery care, while building the governance and audience to move quickly if rules change.
Can telehealth prescribe peptides? FDA-approved peptide drugs, yes: semaglutide, tirzepatide, teriparatide, and the rest are prescribed by telehealth every day under the usual state and DEA rules. Compounded peptides are narrower. Sermorelin, NAD+, and PT-141 programs run today; of the twelve peptides FDA moved off 503A Category 2 in April 2026, six (BPC-157 and TB-500 among them) can be compounded under HHS's October 28 enforcement-discretion conditions, and the rest still wait on rulemaking.
How should a longevity brand prepare for future peptide availability? Three builds: clinical governance that would survive scrutiny, credible educational content that owns patient and AI-engine attention, and a multi-program platform where a new compound is a configuration change rather than a migration.
The category just got a map
Before last week, peptide-curious operators were navigating by rumor. Now there is a defined list, a visible process, and a knowable interval. Regulatory clarity, even partial, is a resource, and it flows to whoever converts it into governance, audience, and infrastructure first.
The votes are in the record. The roadmap is above. The interval has already started.